Tumor mutation burden testing: a survey of the International Quality Network for Pathology (IQN Path)

While tumour mutation burden (TMB) is emerging as a possible biomarker for immune-checkpoint inhibitors (ICI), methods for testing have not been standardised as yet. In April 2019, the International Quality Network for Pathology (IQN Path) launched a survey to assess the current practice of TMB test...

Descripción completa

Detalles Bibliográficos
Autores principales: Fenizia, Francesca, Wolstenholme, Nicola, Fairley, Jennifer A., Rouleau, Etienne, Cheetham, Melanie H., Horan, Martin P., Torlakovic, Emina, Besse, Benjamin, Al Dieri, Raed, Tiniakos, Dina G., Deans, Zandra C., Patton, Simon J., Normanno, Nicola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724102/
https://www.ncbi.nlm.nih.gov/pubmed/33856555
http://dx.doi.org/10.1007/s00428-021-03093-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724102/
https://www.ncbi.nlm.nih.gov/pubmed/33856555
http://dx.doi.org/10.1007/s00428-021-03093-7

Ejemplares similares